Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

MRI and PET/CT of patients with bone metastases from breast carcinoma.

Grankvist J, Fisker R, Iyer V, Fründ ET, Simonsen C, Christensen T, Stenbygaard L, Ewertz M, Larsson EM.

Eur J Radiol. 2012 Jan;81(1):e13-8. doi: 10.1016/j.ejrad.2010.10.024. Epub 2011 Jan 12.

PMID:
21227614
2.

Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.

Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A.

Eur Radiol. 2007 Apr;17(4):939-49. Epub 2006 Sep 2.

PMID:
16951929
3.

"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?

Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G.

Eur J Radiol. 2011 Jun;78(3):430-5. doi: 10.1016/j.ejrad.2009.10.031. Epub 2009 Nov 27.

PMID:
19945240
4.

Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy.

Goudarzi B, Kishimoto R, Komatsu S, Ishikawa H, Yoshikawa K, Kandatsu S, Obata T.

Magn Reson Imaging. 2010 Apr;28(3):372-9. doi: 10.1016/j.mri.2009.12.008. Epub 2010 Jan 27.

PMID:
20106624
5.

Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.

Pauls S, Schmidt SA, Juchems MS, Klass O, Luster M, Reske SN, Brambs HJ, Feuerlein S.

Eur J Radiol. 2012 Jan;81(1):178-82. doi: 10.1016/j.ejrad.2010.09.001. Epub 2010 Oct 6.

PMID:
20932700
6.

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M.

Haematologica. 2007 Jan;92(1):50-5.

7.

Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.

Schmidt GP, Baur-Melnyk A, Haug A, Utzschneider S, Becker CR, Tiling R, Reiser MF, Hermann KA.

Eur Radiol. 2009 Jun;19(6):1366-78. doi: 10.1007/s00330-008-1289-y. Epub 2009 Feb 4.

PMID:
19190917
8.

Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.

Sakurai Y, Kawai H, Iwano S, Ito S, Ogawa H, Naganawa S.

J Med Imaging Radiat Oncol. 2013 Jun;57(3):297-305. doi: 10.1111/1754-9485.12020. Epub 2012 Dec 28.

PMID:
23721138
9.

Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?

Chen W, Jian W, Li HT, Li C, Zhang YK, Xie B, Zhou DQ, Dai YM, Lin Y, Lu M, Huang XQ, Xu CX, Chen L.

Magn Reson Imaging. 2010 Jun;28(5):613-20. doi: 10.1016/j.mri.2010.02.009. Epub 2010 Apr 24.

PMID:
20418042
10.

Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.

van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, Nievelstein RA, de Klerk JM.

AJR Am J Roentgenol. 2011 Mar;196(3):662-9. doi: 10.2214/AJR.10.4743.

PMID:
21343511
11.

18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.

Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF.

J Nucl Med. 2005 Jul;46(7):1136-43.

12.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
13.
14.

Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.

Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ.

Eur J Med Res. 2006 Feb 21;11(2):58-65.

PMID:
16504962
15.
16.

18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.

Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M.

J Nucl Med. 2008 Feb;49(2):195-200. doi: 10.2967/jnumed.107.045641. Epub 2008 Jan 16.

17.

Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.

Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL.

AJR Am J Roentgenol. 2011 Sep;197(3):W384-91. doi: 10.2214/AJR.10.5692.

PMID:
21862763
19.

Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.

Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.

Pediatr Blood Cancer. 2007 Dec;49(7):901-5.

PMID:
17252575
20.

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1766-74. doi: 10.1007/s00259-008-0788-z. Epub 2008 May 9.

PMID:
18465129

Supplemental Content

Support Center